BMEA BIOMEA FUSION INC

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Upcoming Investor Conferences

SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences:

  • Piper Sandler 37th Annual Healthcare Conference: Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings on December 2, 2025 in New York, NY.



  • 8th Annual Evercore Healthcare Conference: Biomea will participate in a Fireside Chat at 7:30 AM (EST) and in one-on-one meetings on December 3, 2025 in Coral Gables, FL.

An audio webcast of the presentations will be available or by visiting the News & Events Page under the section of Biomea’s website. A replay of the webcasts will be available following the live event.

About Biomea Fusion  

Biomea Fusion is a clinical-stage biopharmaceutical company advancing oral small molecule therapies for diabetes and obesity; icovamenib, a selective menin inhibitor for diabetes and BMF-650, a next generation oral GLP-1 receptor agonist for obesity. These programs target cardio metabolic disorders, a global health challenge affecting nearly half of Americans and one-fifth of the world’s population. Biomea’s mission is to deliver transformative treatments that restore health for patients living with diabetes, obesity, and related conditions. We aim to cure.

 

Visit us at biomeafusion.com and follow us on ,  and . 

 

Contact:

Meichiel Jennifer Weiss

Sr. Director of Investor Relations and Corporate Development

 



EN
24/11/2025

Underlying

BMEABIOMEA FUSION INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOMEA FUSION INC

 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Participate at Upcoming Investor Conferences

Biomea Fusion to Participate at Upcoming Investor Conferences SAN CARLOS, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it will participate in the upcoming investor conferences: Piper Sandler 37th Annual Healthcare Conference: Biomea will participate in a fireside chat at 8:00 AM (EST) and in one-on-one meetings on December 2, 2025 in New York, NY.8th Annual Evercore Healthcare Conference: Biomea will participate in a Fireside Chat at 7:30 AM ...

2h / 50m 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Participate at Jefferies London Healthcare Conference

Biomea Fusion to Participate at Jefferies London Healthcare Conference SAN CARLOS, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that it is scheduled to participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on November 17, 2025 at 4:30 PM (GMT) and will participate in one-on-one meetings on November 17-18, 2025 in London, UK. An audio webcast of the presentation will be available or by visiting the News & Events Pag...

November 10, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovameni...

Biomea Fusion Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide at ObesityWeek® 2025 The Company’s investigational small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys A Phase I study of BMF-650 in healthy obese patients is currently enrolling with data expected first half of 2026In a rodent model of type 2 diabetes (“T2D”), icovamenib in combination with low dose semaglutide promoted enhanced glycemic control and body weight reduction with preser...

November 5, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corpora...

Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights Advances diabetes and obesity programs with icovamenib demonstrating durable 52-Week Phase II data and with BMF-650, Biomea’s next-generation, oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), dosing its first patient in a Phase I clinical trialPresented preclinical activity of icovamenib in combination with semaglutide in type 2 diabetes (“T2D”) animal model at EASD Annual Meeting, demonstrating enhanced glycemic control and body weight reduction with preservation of lean massRa...

November 4, 2025 1 EN
 PRESS RELEASE
Free
BMEA BIOMEA FUSION I...

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025

Biomea Fusion to Present Poster Presentations at ObesityWeek®2025 SAN CARLOS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that it will present poster presentations at ObesityWeek® 2025, taking place November 4-7, 2025 in Atlanta, Georgia. The presentations will highlight preclinical data for BMF-650, Biomea’s next-generation oral small molecule glucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), and combination data for icovamenib, the company’s first-in-class cova...

October 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch